Patents by Inventor Christopher C. Corless

Christopher C. Corless has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Platelet derived growth factor receptor alpha (PDGFRA) polypeptides comprising activating mutation(s)
    Patent number: 8202969
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: June 19, 2012
    Assignees: Oregon Health & Science University, U.S. Department of Veteran Affairs, Dana-Farber Cancer Institute, Brigham and Women's Hospital
    Inventors: Michael C. Heinrich, Christopher C. Corless, Jonathan A. Fletcher, George D. Demetri
  • ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGET
    Publication number: 20110081730
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Application
    Filed: December 3, 2010
    Publication date: April 7, 2011
    Inventors: MICHAEL C. HEINRICH, CHRISTOPHER C. CORLESS, JONATHAN A. FLETCHER, GEORGE D. DEMETRI
  • Nucleic acids encoding platelet derived growth factor receptor alpha (PDGFRA) activating mutations
    Patent number: 7875710
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: January 25, 2011
    Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans Affairs, Dana-Faber Cancer Institute, Brigham and Women's Hospital
    Inventors: Michael C. Heinrich, Christopher C. Corless, Jonathan A. Fletcher, George D. Demetri
  • ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS
    Publication number: 20090280495
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Application
    Filed: May 14, 2009
    Publication date: November 12, 2009
    Inventors: Michael C. Heinrich, Christopher C. Corless, Jonathan A. Fletcher, George D. Demetri
  • Method of detecting a neoplasia associated with an activating platelet derived growth factor receptor alpha (PDGFRA) mutation
    Patent number: 7595154
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: September 29, 2009
    Assignees: Oregon Health and Science University, Dana-Farber Cancer Institute, Brigham and Women's Hospital
    Inventors: Michael C. Heinrich, Christopher C. Corless, Jonathan A. Fletcher, George D. Demetri